RCEL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

17.31M

-6.22%

-0.343

-22.2%

19.36M

+4.79%

-0.292

-44.74%

20.88M

+13.1%

-0.275

-27.69%

Estimates Revision

The market is revising No Change the revenue expectations for AVITA Medical, Inc. (RCEL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -40.69%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-40.69%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast RCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCEL is 8.38 USD with a low forecast of 3.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

8.38

High

14.00

Current: 0.000

Low

3.00

Averages

8.38

High

14.00

BTIG

Sell -> Neutral

upgrade

2025-11-20

Reason

BTIG

Price Target

2025-11-20

upgrade

Sell -> Neutral

Reason

BTIG upgraded Avita Medical to Neutral from Sell with no price target following Q3 results and the CEO change that occurred as a result. Shares are down about 71% year-to-date and the firm thinks the company's "wounds are starting to heal or at least cannot get materially much worse," the analyst tells investors. While the firm shares are not quite at a place where it can recommend them, it adds that it is not inclined to recommend selling anymore either.

Lake Street

Hold

downgrade

$4 -> $3

2025-11-07

Reason

Lake Street

Price Target

$4 -> $3

2025-11-07

downgrade

Hold

Reason

Lake Street lowered the firm's price target on Avita Medical to $3 from $4 and keeps a Hold rating on the shares. The firm remains on the sidelines until seeing sales stabilization and reacceleration and a more permanent financial solution to the balance sheet, the analyst tells investors in a post-earnings note.

TD Cowen

Buy

downgrade

2025-10-20

Reason

TD Cowen

Price Target

2025-10-20

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Avita Medical to $5.50 from $8 and keeps a Buy rating on the shares. The firm noted Avita Medical is moving through a leadership transition, but the interim CEO is an industry veteran who will focus on a Board-backed plan centered on execution. The roughly $17M preliminary 3Q revenue result underscores that reimbursement friction was real and lasted longer than hoped, but management believes the policy side is largely fixed exiting 3Q.

Lake Street

Frank Takkinen

Buy

Hold

downgrade

$8 -> $4

2025-10-17

Reason

Lake Street

Frank Takkinen

Price Target

$8 -> $4

2025-10-17

downgrade

Buy

Hold

Reason

Lake Street analyst Frank Takkinen downgraded Avita Medical to Hold from Buy with a price target of $4, down from $8. Q3 revenue did not rebound as anticipated and Jim Corbett resigned as CEO, with Chairman Cary Vance assuming the role as interim CEO, the analyst says. The firm is downgrading shares given the Q3 shortfall, a likely guidance reset, and OrbiMed debt requiring amendments, the analyst noted.

Lake Street

Buy

downgrade

$14 -> $8

2025-08-11

Reason

Lake Street

Price Target

$14 -> $8

2025-08-11

downgrade

Buy

Reason

Lake Street assumed coverage of Avita Medical with a Buy rating and a price target of $8, down from $14. Although guidance was cut materially, the company reiterated confidence in a second half recovery and the firm views this as \"a prudent reset rather than a structural impairment,\" the analyst tells investors.

BTIG

Neutral -> Sell

downgrade

2025-08-08

Reason

BTIG

Price Target

2025-08-08

downgrade

Neutral -> Sell

Reason

BTIG downgraded Avita Medical to Sell from Neutral with a $3 price target. The company reported another quarterly miss and has reduced guidance in five of the last last quarters, the analyst tells investors in a research note. The firm believes Avita is in a \"very challenging position\" as reimbursement to providers via Medicare Administrative Contractors were not being paid despite submitting claims for usage through the the first half of 2025. BTIG sees Recell demand continuing to drop as providers avoid risk of not being paid. It believes the shares have downside risk as Avita works to remain solvent.

Valuation Metrics

The current forward P/E ratio for AVITA Medical Inc (RCEL.O) is -2.93, compared to its 5-year average forward P/E of -4.14. For a more detailed relative valuation and DCF analysis to assess AVITA Medical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.14

Current PE

-2.93

Overvalued PE

10.24

Undervalued PE

-18.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

15.31

Current EV/EBITDA

-5.20

Overvalued EV/EBITDA

106.89

Undervalued EV/EBITDA

-76.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.23

Current PS

1.28

Overvalued PS

11.38

Undervalued PS

1.08

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 534.61% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RCEL News & Events

Events Timeline

No data

News

7.0

01-08Globenewswire

Bragar Eagel & Squire Investigates Soleno, Avita, and Coty for Potential Securities Violations

5.0

01-05Globenewswire

AVITA Medical Appoints Joe Woody as Board Director, Lou Panaccio Retires

1.0

2025-12-18Globenewswire

AVITA Medical CEO to Present at 44th Annual J.P. Morgan Healthcare Conference

People Also Watch

Frequently Asked Questions

What is AVITA Medical Inc (RCEL) stock price today?

The current price of RCEL is 3.28 USD — it has decreased -0.3 % in the last trading day.

What is AVITA Medical Inc (RCEL)'s business?

AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.

What is the price predicton of RCEL Stock?

What is AVITA Medical Inc (RCEL)'s revenue for the last quarter?

AVITA Medical Inc revenue for the last quarter amounts to 17.06M USD, decreased -12.71 % YoY.

What is AVITA Medical Inc (RCEL)'s earnings per share (EPS) for the last quarter?

AVITA Medical Inc. EPS for the last quarter amounts to -0.46 USD, decreased -25.81 % YoY.

What changes have occurred in the market's expectations for AVITA Medical Inc (RCEL)'s fundamentals?

How many employees does AVITA Medical Inc (RCEL). have?

AVITA Medical Inc (RCEL) has 260 emplpoyees as of January 09 2026.

What is AVITA Medical Inc (RCEL) market cap?

Today RCEL has the market capitalization of 100.02M USD.